529 related articles for article (PubMed ID: 28994264)
1. Recent advances in malignant melanoma.
Atkinson V
Intern Med J; 2017 Oct; 47(10):1114-1121. PubMed ID: 28994264
[TBL] [Abstract][Full Text] [Related]
2. [Melanoma update].
Longvert C; Saiag P
Rev Med Interne; 2019 Mar; 40(3):178-183. PubMed ID: 30527396
[TBL] [Abstract][Full Text] [Related]
3. The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.
Zhu Z; Liu W; Gotlieb V
Crit Rev Oncol Hematol; 2016 Mar; 99():91-9. PubMed ID: 26708040
[TBL] [Abstract][Full Text] [Related]
4. Molecular genetic and immunotherapeutic targets in metastatic melanoma.
Melis C; Rogiers A; Bechter O; van den Oord JJ
Virchows Arch; 2017 Aug; 471(2):281-293. PubMed ID: 28357489
[TBL] [Abstract][Full Text] [Related]
5. [Targeted therapies for melanoma].
Leiter U; Meier F; Garbe C
Hautarzt; 2014 Jul; 65(7):600-6. PubMed ID: 24962553
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Advances and Treatment Options in Metastatic Melanoma.
Johnson DB; Sosman JA
JAMA Oncol; 2015 Jun; 1(3):380-6. PubMed ID: 26181188
[TBL] [Abstract][Full Text] [Related]
7. [Systemic treatment of inoperable metastasized malignant melanoma].
Gutzmer R; Rauschenberg R; Meier F
Hautarzt; 2016 Jul; 67(7):529-35. PubMed ID: 27164828
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in melanoma: Recent advances and future directions.
Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
[TBL] [Abstract][Full Text] [Related]
9. Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition.
Lau PK; Ascierto PA; McArthur G
Curr Opin Immunol; 2016 Apr; 39():30-8. PubMed ID: 26765776
[TBL] [Abstract][Full Text] [Related]
10. Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs.
Swe T; Kim KB
Clin Exp Metastasis; 2018 Aug; 35(5-6):503-520. PubMed ID: 30019239
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions.
Ralli M; Botticelli A; Visconti IC; Angeletti D; Fiore M; Marchetti P; Lambiase A; de Vincentiis M; Greco A
J Immunol Res; 2020; 2020():9235638. PubMed ID: 32671117
[TBL] [Abstract][Full Text] [Related]
12. No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.
Girotti MR; Saturno G; Lorigan P; Marais R
Mol Oncol; 2014 Sep; 8(6):1140-58. PubMed ID: 25178978
[TBL] [Abstract][Full Text] [Related]
13. [Immunotherapy for malignant melanoma].
Zaremba A; Zimmer L; Griewank KG; Ugurel S; Roesch A; Schadendorf D; Livingstone E
Internist (Berl); 2020 Jul; 61(7):669-675. PubMed ID: 32462249
[TBL] [Abstract][Full Text] [Related]
14. An Overview of the Changing Landscape of Treatment for Advanced Melanoma.
Lee CS; Thomas CM; Ng KE
Pharmacotherapy; 2017 Mar; 37(3):319-333. PubMed ID: 28052356
[TBL] [Abstract][Full Text] [Related]
15. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
Goldman C; Tchack J; Robinson EM; Han SW; Moran U; Polsky D; Berman RS; Shapiro RL; Ott PA; Osman I; Zhong H; Pavlick AC; Wilson MA
Oncology; 2017; 93(3):164-176. PubMed ID: 28601879
[TBL] [Abstract][Full Text] [Related]
16. Systemic therapy for previously untreated advanced BRAF-mutated melanoma: navigating a shifting landscape.
Levine O; Devji T; Xie F
Immunotherapy; 2017 Mar; 9(5):375-378. PubMed ID: 28357918
[No Abstract] [Full Text] [Related]
17. Targeted agents and immunotherapies: optimizing outcomes in melanoma.
Luke JJ; Flaherty KT; Ribas A; Long GV
Nat Rev Clin Oncol; 2017 Aug; 14(8):463-482. PubMed ID: 28374786
[TBL] [Abstract][Full Text] [Related]
18. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; RĂ©gis JM; Grob JJ
Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.
Kakavand H; Wilmott JS; Long GV; Scolyer RA
Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392
[TBL] [Abstract][Full Text] [Related]
20. Melanoma: from darkness to promise.
Gasent Blesa JM; Grande Pulido E; Alberola Candel V; Provencio Pulla M
Am J Clin Oncol; 2011 Apr; 34(2):179-87. PubMed ID: 20498590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]